Tirzepatide Dosing Schedule: How Titration Works

The short answer: Standard tirzepatide titration starts at 2.5 mg once weekly for four weeks, then steps up in 2.5 mg increments about every four weeks as tolerated, up to a maximum maintenance dose of 15 mg. Starting low and going slow limits gastrointestinal side effects. Your provider sets your actual schedule; this is information, not a personal prescription.

The standard titration schedule

Tirzepatide is a once-weekly injection, and the dose is not fixed at the start of treatment — it climbs on a schedule. The pattern below reflects the FDA-approved prescribing information for branded tirzepatide (Eli Lilly's Zepbound® for weight management and Mounjaro® for type 2 diabetes). It is the reference schedule prescribers generally work from; it is not a compounded-specific dose table sanctioned by the FDA.

The core rule is simple: begin at 2.5 mg once weekly, hold there for four weeks, then increase by 2.5 mg at a time, no sooner than every four weeks, only as tolerated. The 2.5 mg dose is an initiation dose meant to let the body adjust — it is not considered a treatment-level dose. The FDA-approved product comes in six once-weekly strengths: 2.5, 5, 7.5, 10, 12.5, and 15 mg. The recommended maintenance doses are 5, 10, or 15 mg, and 15 mg is the ceiling.

Source: the FDA-approved prescribing information for branded tirzepatide (Zepbound®/Mounjaro®). Step timing is a minimum, not a mandate — providers can hold a dose longer or stop stepping up. This is the standard schedule for the branded, FDA-approved product; your provider sets your actual schedule, and compounded dosing is determined by the prescriber.

Why tirzepatide is titrated at all

The reason for the slow climb is tolerability. Tirzepatide acts on gut and metabolic signaling, and the most common side effects — nausea, diarrhea, vomiting, constipation — are usually at their worst right after a dose increase. Ramping up gradually gives the digestive system time to adapt, which is why the FDA-approved prescribing information builds in the 2.5 mg start and the four-week holds rather than beginning at a treatment dose.

Titration is also why the headline efficacy figures come from the top of the ladder. In SURMOUNT-1, the pivotal trial of branded tirzepatide, participants without diabetes who reached the highest dose alongside diet and exercise lost about 24.3% of body weight on average over 72 weeks (Jastreboff et al., NEJM 2022). That average was measured after months of gradual dose escalation — not from day one — and it is a clinical-trial average for the FDA-approved drug. Individual results vary and are not guaranteed.

Finding a maintenance dose

There is no single "right" tirzepatide dose. The goal is the lowest dose that achieves your target with side effects you can live with — which is why the label defines three maintenance options (5, 10, and 15 mg) rather than pushing everyone to the maximum. Some people do well at 5 mg and never move up; others step up to 10 or 15 mg over several months. Moving up faster does not linearly buy more benefit, and it can worsen GI symptoms.

If side effects are difficult at a given step, a provider may keep you at the current dose longer before increasing, or hold off on the next step entirely. Because tirzepatide is titrated over months, patience is part of the design. In SURMOUNT-1, dose escalation to the maintenance levels was spread across the opening weeks precisely so participants could tolerate the target dose — the same logic applies in practice.

Missed-dose basics

Because tirzepatide is dosed once a week, an occasional missed injection is common. The general guidance in the FDA-approved prescribing information is that if you remember within a few days of the missed dose, you can take it; if it is close to the day of your next scheduled dose, it may be better to skip the missed one and resume your normal weekly schedule. You should not take two doses close together to "catch up."

That is general label-level information, not a personal instruction. Product formulations and provider protocols differ, so the safe move is to follow the directions on your specific product's label and the guidance your prescriber gave you — and to contact them if you are unsure. This page cannot tell you what to do with your own missed dose.

Side effects, at a high level

Most tirzepatide side effects are gastrointestinal and dose-related: nausea, diarrhea, vomiting, and constipation are the most frequently reported, and they tend to be transient, easing as the body adjusts to a given dose. This is exactly why the schedule ramps slowly. Even so, side effects are real, and some people find a particular step hard to tolerate.

There are also serious warnings. Branded tirzepatide carries a boxed warning regarding thyroid C-cell tumors based on rodent studies, and it is not for people with a personal or family history of medullary thyroid carcinoma or MEN 2. Rarer but serious risks discussed in the prescribing information include pancreatitis and gallbladder problems. This guide covers side effects only at a high level — a licensed provider must review your full medical history and manage any symptoms. If you have severe or persistent symptoms, contact your provider.

How compounded dosing differs

Everything above describes the branded, FDA-approved product. Compounded tirzepatide is a different situation: it is not FDA-approved, and there is no FDA-sanctioned dose table specific to compounded versions. Prescribers generally base compounded titration on the same principles as the branded schedule — start low, step up slowly — but the actual dose, the increments, and the timing are determined by the licensed provider, and a compounded vial's concentration may not map onto a branded strength.

The practical takeaway: do not assume a compounded dose equals a branded milligram figure, and do not self-adjust. Follow the exact instructions your provider and pharmacy give you. If you want to understand how tirzepatide compares to semaglutide on effect and dosing cadence, our tirzepatide vs. semaglutide guide breaks it down, and our methodology explains how we evaluate programs.

The bottom line

Tirzepatide dosing is a deliberate, months-long climb: 2.5 mg to start, 2.5 mg step-ups about every four weeks, maintenance at 5, 10, or 15 mg, with 15 mg the maximum. The slow ramp exists to keep side effects manageable while the body adjusts. Those figures describe the FDA-approved branded product; compounded tirzepatide is not FDA-approved, and in every case your actual schedule is set by a licensed provider — not by a chart on a webpage.